1. Faderl S, O'Brien S, Pui CH, et al. Adult acute lymphoblastic leukemia: concepts and strategies. Cancer. 2010; 116:1165–1176. PMID:
20101737.
2. Tafuri A, Milella M, Iacovelli S, et al. Aberrant proliferative and apoptotic pathways in acute lymphoblastic leukemia (ALL): Molecular therapies to overcome chemo-resistance. In : Stefan Faderl, editor. Novel aspects in acute lymphoblastic leukemia. Rijeka, Croatia: InTech;2011. p. 183–210.
3. Dördelmann M, Reiter A, Borkhardt A, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood. 1999; 94:1209–1217. PMID:
10438708.
4. Klumper E, Pieters R, Veerman AJ, et al. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood. 1995; 86:3861–3868. PMID:
7579354.
Article
5. Kaspers GJ, Wijnands JJ, Hartmann R, et al. Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia. Eur J Cancer. 2005; 41:1300–1303. PMID:
15869873.
Article
6. Beesley AH, Firth MJ, Ford J, et al. Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism. Br J Cancer. 2009; 100:1926–1936. PMID:
19436302.
Article
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100:57–70. PMID:
10647931.
Article
8. Hogarth LA, Hall AG. Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood. 1999; 93:2671–2678. PMID:
10194447.
Article
9. Campana D, Coustan-Smith E, Manabe A, et al. Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein. Blood. 1993; 81:1025–1031. PMID:
8427984.
Article
10. Coustan-Smith E, Kitanaka A, Pui CH, et al. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia. Blood. 1996; 87:1140–1146. PMID:
8562940.
Article
11. Signorelli P, Ghidoni R. Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J Nutr Biochem. 2005; 16:449–466. PMID:
16043028.
Article
12. Lin MT, Yen ML, Lin CY, Kuo ML. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol. 2003; 64:1029–1036. PMID:
14573751.
Article
13. Seve M, Chimienti F, Devergnas S, et al. Resveratrol enhances UVA-induced DNA damage in HaCaT human keratinocytes. Med Chem. 2005; 1:629–633. PMID:
16787346.
Article
14. Cullberg K, Foldager C, Lind M, Richelsen B, Pedersen S. Inhibitory effects of resveratrol on hypoxia-induced inflammation in 3T3-L1 adipocytes and macrophages. J Funct Foods. 2014; 7:171–179.
Article
15. Fan GH, Wang ZM, Yang X, et al. Resveratrol inhibits oesophageal adenocarcinoma cell proliferation via AMP-activated protein kinase signaling. Asian Pac J Cancer Prev. 2014; 15:677–682. PMID:
24568477.
Article
16. Lephart ED, Sommerfeldt JM, Andrus MB. Resveratrol: influences on gene expression in human skin. J Funct Foods. 2014; 10:377–384.
Article
17. Gupta SC, Kannappan R, Reuter S, Kim JH, Aggarwal BB. Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci. 2011; 1215:150–160. PMID:
21261654.
Article
18. Dewson G, Kluck RM. Bcl-2 family-regulated apoptosis in health and disease. Cell Health Cytoskelet. 2010; 2:9–22.
19. Wojcik I, Szybka M, Golanska E, et al. Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias. Neoplasma. 2004; 52:318–324.
20. Azimi A, Hagh MF, Talebi M, et al. Time-and concentration-dependent effects of resveratrol on miR 15a and miR16-1 expression and apoptosis in the CCRF-CEM acute lymphoblastic leukemia cell line. Asian Pac J Cancer Prev. 2015; 16:6463–6468. PMID:
26434860.
21. Tzifi F, Economopoulou C, Gourgiotis D, Ardavanis A, Papageorgiou S, Scorilas A. The role of BCL2 family of apoptosis regulator proteins in acute and chronic leukemias. Adv Hematol. 2012; 2012:524308. PMID:
21941553.
Article
22. Winick NJ, Carroll WL, Hunger SP. Childhood leukemia-new advances and challenges. N Engl J Med. 2004; 351:601–603. PMID:
15295054.
23. Yin HT, Tian QZ, Guan L, Zhou Y, Huang XE, Zhang H. In vitro and in vivo evaluation of the antitumor efficiency of resveratrol against lung cancer. Asian Pac J Cancer Prev. 2013; 14:1703–1706. PMID:
23679260.
Article
24. Jazirehi AR, Bonavida B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther. 2004; 3:71–84. PMID:
14749477.
25. Fulda S, Debatin KM. Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene. 2004; 23:6702–6711. PMID:
15273734.
Article
26. Bhardwaj A, Sethi G, Vadhan-Raj S, et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood. 2007; 109:2293–2302. PMID:
17164350.
27. Fouad MA, Agha AM, Merzabani MM, Shouman SA. Resveratrol inhibits proliferation, angiogenesis and induces apoptosis in colon cancer cells: calorie restriction is the force to the cytotoxicity. Hum Exp Toxicol. 2013; 32:1067–1080. PMID:
23536519.
28. Dörrie J, Gerauer H, Wachter Y, Zunino SJ. Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res. 2001; 61:4731–4739. PMID:
11406544.
29. Estrov Z, Shishodia S, Faderl S, et al. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood. 2003; 102:987–995. PMID:
12689943.
30. Cecchinato V, Chiaramonte R, Nizzardo M, et al. Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells. Biochem Pharmacol. 2007; 74:1568–1574. PMID:
17868649.
Article